Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Post-Mkt 12-11 18:29:50 EST

0.9984

+0.0088

+0.89%

盘后0.9984

+0.00000.00%

18:23 EST

High1.00	Low0.9625	Vol313.27K
Open0.9900	D1 Closing0.9896	Amplitude3.79%
Mkt Cap107.83M	Tradable Cap105.83M	Total Shares108.00M
T/O308.29K	T/O Rate0.30%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.9984,"timestamp":1765486800000,"preClose":0.9896,"halted":0,"volume":313265,"hourTrading":{"tag":"盘后","latestPrice":0.9984,"preClose":0.9984,"latestTime":"18:23 EST","volume":97,"amount":96.3575981,"timestamp":1765495391063},"delay":0,"floatShares":106000000,"shares":108000000,"eps":-0.285545,"marketStatus":"Post-Mkt","change":0.0088,"latestTime":"12-11 18:29:50 EST","open":0.99,"high":1,"low":0.9625,"amount":308285.10774390004,"amplitude":0.037894,"askPrice":1.01,"askSize":30,"bidPrice":0.975,"bidSize":49,"shortable":3,"etf":0,"ttmEps":-0.285545,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.9896,"preHourTrading":{"tag":"盘前","latestPrice":1,"preClose":0.9896,"latestTime":"09:21 EST","volume":9695,"amount":9651.503382500001,"timestamp":1765462910351},"postHourTrading":{"tag":"盘后","latestPrice":0.9984,"preClose":0.9984,"latestTime":"18:23 EST","volume":97,"amount":96.3575981,"timestamp":1765495391063},"volumeRatio":0.461391},"requestUrl":"/m/hq/s/ONCY/tweets","defaultTab":"tweets","newsList":[{"id":"2590732774","title":"BRIEF-Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada","url":"https://stock-news.laohu8.com/highlight/detail?id=2590732774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590732774?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:02","pubTimestamp":1765321356,"startTime":"0","endTime":"0","summary":"BRIEF-Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To NevadaDec 9 (Reuters) - Oncolytics Biotech Inc ONCY.O:ONCOLYTICS BIOTECH RESCHEDULES SPE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2590327766","title":"Oncolytics Biotech Inc - Reschedules Special Meeting to January 15, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590327766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590327766?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:00","pubTimestamp":1765321225,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0M6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2585168523","title":"BRIEF-Oncolytics Biotech® Provides Update On Special Meeting Of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168523?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:43","pubTimestamp":1763675039,"startTime":"0","endTime":"0","summary":"BRIEF-Oncolytics Biotech Provides Update On Special Meeting Of ShareholdersNov 20 (Reuters) - Oncolytics Biotech Inc ONCY.O:ONCOLYTICS BIOTECH PROVIDES UPDATE ON SPECIAL MEETING OF SHAREHOLDERSONCOLYT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA8MR85G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2585157718","title":"Oncolytics Biotech Plans Move from Alberta to Nevada","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157718","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157718?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:06","pubTimestamp":1763672761,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing pelareorep, has announced plans for a corporate reorganization involving a change of jurisdiction from Alberta, Canada to the State of Nevada, USA. The company was set to hold a special meeting of shareholders to vote on this and other related transactions but has postponed the meeting due to delays at the U.S. Securities and Exchange Commission caused by a recent federal government shutdown. Oncolytics intends to reschedule the meeting as soon as practicable.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via Business Wire  on November 20, 2025, and is solely responsible for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL6w1QLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2585504961","title":"Oncolytics Biotech Inc - Special Meeting Rescheduled Due to U.S. Government Shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2585504961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585504961?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA8MR85G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2585150495","title":"Oncolytics Biotech Inc - Cancels and Will Reschedule Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150495?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA8MR85G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2585115721","title":"Oncolytics Biotech® Provides Update on Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2585115721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585115721?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA8MR85G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2584137353","title":"Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584137353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584137353?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:56","pubTimestamp":1763646979,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $7.00. Messer covers the Healthcare s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY"],"gpt_icon":0},{"id":"2584179135","title":"Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584179135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584179135?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:38","pubTimestamp":1763638716,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $3.50. According to TipRanks, M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oncolytics-biotech-oncy-gets-a-buy-from-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oncolytics-biotech-oncy-gets-a-buy-from-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU0708994859.HKD","LU0029864427.USD","LU0310800379.SGD","BK4139","LU0128525929.USD","ONCY","BK4207"],"gpt_icon":0},{"id":"2584920227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920227?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:59","pubTimestamp":1763578756,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSTR","ACHR","GEV","XOM","PPL","NEM","NUVL","ON","RDW","LZB","STX","WDC","DOW","OXY","VTVT","DY","OKLO","GLBE","ZION","OWL","NVDA","SCCO","LOW","NNOX","CVX","OLMA","PLUG","PRAX","CDE","ONCY","TGT","VVV","COP","COIN","CEVA","RIOT","SION","ALZN","AGIO","FCX","GOOGL","SHBI","RAPP","GLAD","DLB","KZIA","H","NNE","SNDK","CSIQ"],"gpt_icon":0},{"id":"2584928455","title":"Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584928455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584928455?lang=en_us&edition=fundamental","pubTime":"2025-11-19 23:30","pubTimestamp":1763566219,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Avadel Pharmaceuticals (AVDL – Research Report) and Oncolytics Biotech (ONCY – Research Report) with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avadel-pharmaceuticals-avdl-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avadel-pharmaceuticals-avdl-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4007","LU0128526141.USD","LABU","ONCY","LU0029874061.USD","BK4585","BK4588","XLV","AVDL","HCSG","XBI","BK4139","BK4581"],"gpt_icon":0},{"id":"2584483947","title":"BUZZ-Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584483947","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584483947?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:35","pubTimestamp":1763562919,"startTime":"0","endTime":"0","summary":"BUZZ-Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial** U.S.-listed shares of Oncolytics Biotech ONCY.O rise 5.7% to $1.09 premarket ** Co says it has reached an agreement with the U.S. FDA on the design of a major clinical trial for its experimental cancer drug, pelareorep, in patients with advanced pancreatic cancer** Pancreatic cancer is an aggressive disease with limited treatment options; trial aims to add immunotherapy to standard chemo - ONCY** ONCY says main goal is overall survival** Co says study will compare chemo alone vs. chemo plus pelareorep, with an option to add another type of cancer drug called a checkpoint inhibitor** Pelareorep has shown promise in earlier pancreatic and breast cancer studies; both programs have FDA Fast Track status - ONCY** Up to last close, stock up 13% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2584942441","title":"Oncolytics aligns with FDA on pelareorep study design","url":"https://stock-news.laohu8.com/highlight/detail?id=2584942441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584942441?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:10","pubTimestamp":1763561413,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced alignment with the FDA regarding the design of its pivotal study of pelareorep in combination with standard-of-care the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-pelareorep-study-design-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-pelareorep-study-design-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2584942510","title":"BRIEF-Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584942510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584942510?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:09","pubTimestamp":1763561340,"startTime":"0","endTime":"0","summary":"BRIEF-Oncolytics Biotech Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic CancerOncolytics Biotech Inc ONCY.O:ONCOLYTICS BIOTECH ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2584944087","title":"Oncolytics Biotech® Aligns With FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944087?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:00","pubTimestamp":1763560813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2584048944","title":"Oncolytics Biotech Inc - to Launch Immunotherapy Trial in Pancreatic Cancer in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584048944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584048944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:00","pubTimestamp":1763560813,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0JD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2584362873","title":"Oncolytics Biotech Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584362873","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584362873?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:26","pubTimestamp":1763382360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 07:26 ET (12:26 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2578955529","title":"Oncolytics reports updated results from study of pelareorep plus atezolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2578955529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578955529?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:35","pubTimestamp":1761651327,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study evaluating pelareor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-updated-results-from-study-of-pelareorep-plus-atezolizumab-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-updated-results-from-study-of-pelareorep-plus-atezolizumab-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2578953079","title":"Oncolytics Biotech Reports Pelareorep Combo Doubles Response Rate in Advanced Anal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578953079","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578953079?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:30","pubTimestamp":1761651050,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has announced updated results from the squamous cell anal carcinoma  cohort of the GOBLET study, evaluating pelareorep in combination with atezolizumab  in patients with second-line or later (≥2L) metastatic SCAC. The combination achieved an objective response rate  of 30% among 20 evaluable patients, which is more than double the 13.8% historical benchmark for the only FDA-approved immunotherapy in this setting. The median duration of response was 15.5 months, compared to 9.5 months for the current standard of care. These results have already been presented, and additional efficacy data are expected to be reported as patient follow-up continues. Oncolytics plans to discuss a potential single-arm accelerated approval study with the U.S. Food and Drug Administration  in the first quarter of 2026, with a potential study launch date in the first half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL1BB3t9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2578953473","title":"Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2578953473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578953473?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:30","pubTimestamp":1761651000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA6CML1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0917},{"period":"1month","weight":-0.0751},{"period":"3month","weight":-0.2446},{"period":"6month","weight":0.6276},{"period":"1year","weight":0.152},{"period":"ytd","weight":0.083}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.015183},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.050372},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.105719},{"month":4,"riseRate":0.714286,"avgChangeRate":0.022868},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.009291},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.285029}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction